Guotai Junan Securities maintains a "buy" rating on Cinda Biotechnology (01801.HK) as it breaks through the second growth curve in the comprehensive pipeline field.

According to the Securities Times APP, China Galaxy Securities released a research report stating that Sundia Bio (01801.HK) has become a leading domestic Biopharma company integrating innovative drug research and development, production, and commercialization, with a solid leading position in the field of oncology, continuously leading growth; breakthrough the second growth curve in the comprehensive pipeline field, providing room for imagination for the company's medium and long-term development. The bank expects the company's operating income for 2025-2027 to be 11.891 billion, 14.836 billion, and 20.029 billion respectively; net profit attributable to shareholders will be 824 million, 1.378 billion, and 2.059 billion respectively, while maintaining a "recommended" rating.